Ampio’s Osteoarthritis Candidate Falls Short in Phase 3 Study

Ampio Pharmaceuticals osteoarthritis candidate Ampion flopped in a Phase 3 trial, failing to meet its primary endpoint of change in pain after 12 weeks compared to saline.

The company will nevertheless seek FDA approval for the candidate. Ampio says it will present safety data to support the clinical benefit, as there were no drug-related safety issues.